Literature DB >> 20818814

Exertional esophageal pH-metry and manometry in recurrent chest pain.

Jacek Budzyński1.   

Abstract

AIM: To investigate the diagnostic efficacy of 24-h and exertional esophageal pH-metry and manometry in patients with recurrent chest pain.
METHODS: The study included 111 patients (54% male) with recurrent angina-like chest pain, non-responsive to therapy with proton pump inhibitors. Sixty-five (59%) had non-obstructive lesions in coronary artery angiography, and in 46 (41%) significant coronary artery narrowing was found. In all patients, 24-h esophageal pH-metry and manometry, and treadmill stress tests with simultaneous esophageal pH-metry and manometry monitoring were performed. During a 24-h examination the percentage of spontaneous chest pain (sCP) episodes associated with acid reflux or dysmotility (symptom index, SI) was calculated. Patients with SI > 50% for acid gastroesophageal reflux (GER) were classified as having GER-related sCP. The remaining symptomatic individuals were determined as having non-GER-related sCP. During the stress test, the occurrence of chest pain, episodes of esophageal acidification (pH < 4 for 10 s) and esophageal spasm with more than 55% of simultaneous contractions (exercise-provoked esophageal spasm or EPES) were noted.
RESULTS: Sixty-eight (61%) individuals reported sCP during 24-h esophageal function monitoring. Eleven of these (16%) were classified as having GER-related sCP and 53/68 (84%) as having non-GER-related sCP. The exercise-provoked chest pain during a stress test occurred in 13/111 (12%) subjects. In order to compare the clinical usefulness of 24-h esophageal function monitoring and its examination limited only to the treadmill stress test, the standard parameters of diagnostic test evaluation were determined. The occurrence of GER-related or non-GER-related sCP was assumed as a "gold standard". Afterwards, accuracy, sensitivity and specificity were calculated. These parameters expressed a prediction of GER-related or non-GER-related sCP occurrence by the presence of chest pain, esophageal acidification and EPES. Accuracy, sensitivity and specificity of chest pain during the stress test predicting any sCP occurrence were 28%, 35% and 80%, respectively, predicting GER-related sCP were 42%, 0% and 83%, respectively, and predicting non-GER-related sCP were 57%, 36% and 83%, respectively. Similar values were obtained for exercise-related acidification with pH < 4 longer than 10 s in the prediction of GER-related sCP (44%, 36% and 92%, respectively) and EPES in relation to non-GER-related sCP (48%, 23% and 84%, respectively).
CONCLUSION: The presence of chest pain, esophageal acidification and EPES had greater than 80% specificity to exclude the GER-related and non-GER-related causes of recurrent chest pain.

Entities:  

Mesh:

Year:  2010        PMID: 20818814      PMCID: PMC2937111          DOI: 10.3748/wjg.v16.i34.4305

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  57 in total

1.  Gastrointestinal profile of symptomatic athletes at rest and during physical exercise.

Authors:  Michiel A van Nieuwenhoven; Fred Brouns; Robert-Jan M Brummer
Journal:  Eur J Appl Physiol       Date:  2003-11-22       Impact factor: 3.078

2.  Exertional gastro-oesophageal reflux: a mechanism for symptoms in patients with angina pectoris and normal coronary angiograms.

Authors:  P M Schofield; D H Bennett; P J Whorwell; N H Brooks; C L Bray; C Ward; P E Jones
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-06

3.  Spontaneous noncardiac chest pain. Evaluation by 24-hour ambulatory esophageal motility and pH monitoring.

Authors:  L Peters; L Maas; D Petty; C Dalton; D Penner; W Wu; D Castell; J Richter
Journal:  Gastroenterology       Date:  1988-04       Impact factor: 22.682

4.  Role of stationary esophageal manometry in clinical practice. Manometric results in patients with gastroesophageal reflux, dysphagia or non-cardiac chest pain.

Authors:  C Ciriza de los Ríos; L García Menéndez; A Díez Hernández; M Delgado Gómez; A L Fernández Eroles; A Vega Fernández; A I San Sebastián; M J Romero Arauzo
Journal:  Rev Esp Enferm Dig       Date:  2004-09       Impact factor: 2.086

5.  Patients with chest pain and occult gastroesophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid suppression.

Authors:  Sanchoy Sarkar; David G Thompson; Clifford J Woolf; Anthony R Hobson; Teri Millane; Qasim Aziz
Journal:  Am J Gastroenterol       Date:  2004-10       Impact factor: 10.864

6.  Reflux esophagitis in the pathogenesis of paroxysmal atrial fibrillation: results of a pilot study.

Authors:  Manuela Weigl; Michael Gschwantler; Edmund Gatterer; Josef Finsterer; Claudia Stöllberger
Journal:  South Med J       Date:  2003-11       Impact factor: 0.954

7.  Investigation of esophageal sensation and biomechanical properties in functional chest pain.

Authors:  I Nasr; A Attaluri; S Hashmi; H Gregersen; S S C Rao
Journal:  Neurogastroenterol Motil       Date:  2010-01-12       Impact factor: 3.598

Review 8.  Current concepts: recognition and management of common activity-related gastrointestinal disorders.

Authors:  Scott A Paluska
Journal:  Phys Sportsmed       Date:  2009-04       Impact factor: 2.241

9.  24-hour recording of esophageal pressure and pH in patients with noncardiac chest pain.

Authors:  J Janssens; G Vantrappen; G Ghillebert
Journal:  Gastroenterology       Date:  1986-06       Impact factor: 22.682

10.  Comorbidities are frequent in patients with gastroesophageal reflux disease in a tertiary health care hospital.

Authors:  Joaquim Prado P Moraes-Filho; Tomás Navarro-Rodriguez; Jaime N Eisig; Ricardo C Barbuti; Decio Chinzon; Eamonn M M Quigley
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more
  1 in total

1.  Clinical utility and tolerability of JSPH-1 wireless esophageal pH monitoring system.

Authors:  Jun-Nan Li; Chun-Lun Liu; Xiao-Hong Tao
Journal:  BMC Gastroenterol       Date:  2013-01-15       Impact factor: 3.067

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.